| Authors: |
Higham SL; Imperial College London, Department of Infectious Disease, London, UK., Wang Z; Imperial College London, Department of Infectious Disease, London, UK., Murugaiah V; Imperial College London, Department of Infectious Disease, London, UK., Song J; Imperial College London, Department of Infectious Disease, London, UK., Thomas C; Imperial College London, Department of Infectious Disease, London, UK., Zhang H; Imperial College London, National Heart and Lung Institute, London, UK., Griesenbach U; Imperial College London, National Heart and Lung Institute, London, UK., Alton EWFW; Imperial College London, National Heart and Lung Institute, London, UK., Granger LA; Imperial College London, Department of Infectious Disease, London, UK., Esparza AF; Imperial College London, Department of Infectious Disease, London, UK., Barbieri BD; Imperial College London, Department of Infectious Disease, London, UK., Hitchen PG; Imperial College London, Department of Life Sciences, London, UK., Kellam P; Imperial College London, Department of Infectious Disease, London, UK.; RQ Biotechnology Ltd, London, UK., Shattock RJ; Imperial College London, Department of Infectious Disease, London, UK., Sriskandan S; Imperial College London, Department of Infectious Disease, London, UK., Reece ST; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, United Kingdom.; Coalition for Epidemic Preparedness Innovations, Oslo, Norway., Tregoning JS; Imperial College London, Department of Infectious Disease, London, UK. john.tregoning@imperial.ac.uk. |
